Close Menu

NEW YORK – Myriad Genetics reported after the close of the market on Monday that its fiscal first quarter 2020 revenues declined by 8 percent year over year, mainly due to changes in CPT codes for hereditary cancer testing.

For the three months ended Sept. 30, revenues decreased to $186.3 million from $202.3 million in the year-ago quarter, well below analysts' average estimate of $202.1 million. Based on the Q1 performance, Myriad lowered its fiscal year 2020 revenue expectations.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).